Meta-analysis of the efficacy and safety of α2-adrenergic agonists, β-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs

Archives of Ophthalmology

Volumn 128, Issue 7, 2010, Pages 825-833

  Tanna, Angelo P ^a   Rademaker, Alfred W ^a   Stewart, William C ^b   Feldman, Robert M ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University of South Carolina   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE PURITE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; DORZOLAMIDE; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ALLERGY; ARTICLE; BLUNTED AFFECT; BLURRED VISION; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CONJUNCTIVAL DISCHARGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; EPIPHORA; ETHNICITY; EYE BURNING; EYELID PAIN; FATIGUE; FISHER EXACT TEST; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; INTRAOCULAR PRESSURE ABNORMALITY; LUNG DISEASE; MEDLINE; METHODOLOGY; MONOTHERAPY; NAUSEA; OCULAR SURFACE DISTURBANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUALITY CONTROL; SINUS CONGESTION; TASTE DISORDER; TREATMENT WITHDRAWAL; WEAKNESS; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ADRENERGIC, ALPHA-2; TREATMENT OUTCOME;

EID: 77954963578     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.131     Document Type: Article

References (30)

1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
3. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943-1953.
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
5. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896- 1900.
6. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998;51(12):1235-1241.
7. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177-1185. (Pubitemid 40916921)
8. Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma. 2006;15(4):341-345.
9. Reis R, Queiroz CF, Santos LC, Avila MP, Magacho L. A randomized, investigatormasked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28(4):552-559.
10. Kimal Arici M, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22(1):37-42. (Pubitemid 29083234)
11. Day DG, Hollander DA. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2008;24(5):1435-1442.
12. Lupinacci AP, Netland PA, Fung KH, Evans D, Zhao Y. Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost. Adv Ther. 2008;25(3):231-239.
13. Konstas AG, Karabatsas CH, Lallos N, et al. 24-Hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary openangle glaucoma subjects. Ophthalmology. 2005;112(4):603-608. (Pubitemid 41108860)
14. Holló G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol. 2006;16(6):816-823.
15. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol. 1999;128(6):692-696.
16. Tamer C, Oksuz H. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Ophthalmic Res. 2007;39(1):24-31.
17. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Metaanalysis in Medical Research. London, England: John Wiley; 2000.
18. Feldman RM, Tanna AP, Gross RL, et al; Additivity Study Group. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology. 2007;114(7):1248-1254.
19. Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;131(5):631-635.
20. Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol. 2001;131(6):729-733. (Pubitemid 32522641)
21. Stewart WC, Day DG, Stewart JA, et al. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2000;16(6):557-564.
22. Stewart WC, Sharpe ED, Harbin TS Jr, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol. 2000;129(6):723-727.
23. Stewart WC, Sharpe ED, Day DG, et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2000;16(3):251-259.
24. Silver LH; Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126(3):400-408.
25. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamidetimolol combination to monotherapy with timolol or dorzolamide. Ophthalmology. 1999;106(12)(suppl):17-24.
26. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology. 1999;106(12)(suppl):10-16.
27. Cantor LB, Safyan E, Liu CC, Batoosingh AL. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin. 2008;24(7):2035-2043.
28. Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19(1):37-44. (Pubitemid 36249878)
29. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2):119-126. (Pubitemid 34298592)
30. Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther. 2007;23(5):481-486.